Access cutting-edge alzheimer's disease treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access alzheimer's disease specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alzheimer's disease treatment provided free
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD). Approximately 800 additional participants will be enrolled in a 12-month addendum to assess safety of a different titration regimen.
Sponsor: Eli Lilly and Company
Check if you qualify for this alzheimer's disease clinical trial in Birmingham, AL
If you're searching for alzheimer's disease treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.